Companies › Ocus Innovation Ireland
1 active drug program in 2 registered trials: 2 Phase 3; Ophthalmology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Atropine Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 3 | Myopia | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07028827 | Atropine | Phase 3 | Myopia | Ophthalmology | Dec 2027 |
| NCT07028827 | Atropine | Phase 3 | Myopia | Ophthalmology | Dec 2027 |
ReGenTree Ocumension Therapeutics (Suzhou) Alkeus Pharmaceuticals Laboratorios Sophia S.A de C.V. Cloudbreak Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.